Noiruimunbaiotekku
4893.TTSE GROWTHPharmaceutical
Filed as Noile-Immune Biotech Inc. (2023-08–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥5m | ¥8m | ¥317m | ¥626m | ¥101m | ¥97m |
| Operating income | −¥797m | −¥1.1bn | −¥775m | −¥106m | — | — |
| Ordinary income | −¥791m | −¥962m | −¥1.1bn | −¥384m | −¥793m | −¥605m |
| Total assets | ¥4.0bn | ¥4.8bn | ¥5.8bn | ¥4.6bn | ¥4.3bn | ¥2.7bn |
| Net assets / equity | ¥3.9bn | ¥4.7bn | ¥5.7bn | ¥4.3bn | ¥4.2bn | ¥2.6bn |
| Operating cash flow | −¥752m | −¥888m | −¥873m | −¥107m | −¥777m | −¥301m |
| EPS (basic) | ¥-18.33 | ¥-22.28 | ¥-27.25 | ¥-9.87 | ¥-20.75 | ¥-89.64 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 10
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 61 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 105 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 61 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 104 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-yearAmended | 61 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 61 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 37 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 100 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 27 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 40 figures · EDINET |